Clinical trials: Severe Pain
Ulcerative Colitis
Study of OSE-127 vs Placebo in Patients With Moderate to Severe Active Ulcerative Colitis
This is a phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group study in patients with moderate to severe active ulcerative colitis.
- Trial name
- CoTikiS (NCT04882007)
- Testing
- OSE-127
- Where
- 55 sites in Belarus, Belgium and 9 more
- Volunteers
- 136 people
- Sponsor
- OSE Immunotherapeutics
Trichotillomania
A Study in Patients With Trichotillomania
The purpose of this study is to explore the safety, tolerability and activity of SXC-2023 when dosed for 6 weeks versus placebo in adult patients with moderate to severe Trichotillomania.
- Trial name
- TTM (NCT03797521)
- Testing
- SXC-2023
- Where
- 13 sites in United States
- Volunteers
- 128 people
- Sponsor
- Promentis Pharmaceuticals, Inc.
Moderate to Severe Ulcerative Colitis
A Study Assessing the Efficacy and Safety of CBP-307 in Subjects With Moderate to Severe Ulcerative Colitis (UC)
This study will evaluate the efficacy and safety of CBP-307 in subjects with moderate to severe ulcerative colitis (UC).
- Trial name
- NCT04700449
- Testing
- Double-Blind 0.2mg CBP-307, Open-label CBP-307, Double-Blind 0.1mg CBP-307
- Where
- 66 sites in United States, China and 2 more
- Volunteers
- 145 people
- Sponsor
- Connect Biopharm LLC
Type-2 Diabetes
Pharmacokinetic Study of Vildagliptin in Patients With Renal Impairment
This study will evaluate the pharmacokinetics of vildagliptin and its metabolites in patients with mild, moderate or severe renal impairment and healthy volunteers.
- Trial name
- NCT00567047
- Testing
- vildagliptin
- Where
- 6 sites in United States, Germany
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Novartis
Chronic Pain
Study to Evaluate the Long-Term Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) in Patients Who Require Opioid Treatment for an Extended Period of Time
The primary objective of this study is to evaluate the safety of hydrocodone extended-release tablets when used over a 12-month period in patients with chronic pain, as assessed by adverse events, clinical laboratory results…
- Trial name
- NCT01223365
- Testing
- Hydrocodone ER
- Where
- 54 sites in United States
- Volunteers
- 330 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Aortic Regurgitation
THE ALIGN-AR EFS TRIAL: JenaValve Pericardial TAVR Aortic Regurgitation Study
To collect information about treatment for severe Aortic Regurgitation (AR), which affects the aortic valve in the heart. Aortic regurgitation is a condition where aortic valve in the heart does not close tightly and allows some…
- Trial name
- NCT02732704
- Testing
- JenaValve Pericardial TAVR System
- Where
- 19 sites in United States, Germany and 1 more
- Volunteers
- 100 people
- Sponsor
- JenaValve Technology, Inc.
Uncomplicated Urinary Tract Infections
Safety and Efficacy of Phenazopyridine Hydrochloride Tablets, USP 200 mg as an Analgesic for Short-Term Treatment in Female Subjects Suffering From Moderate-to-Severe Pain and Burning Upon Urination Associated With Uncomplicated Urinary Tract Infections (uUTI)
The primary objective is to evaluate the safety and efficacy of Phenazopyridine HCl Tablets, USP 200 mg as a short term analgesic treatment of pain upon urination associated with Uncomplicated Urinary Tract Infections (uUTI).
- Trial name
- NCT01650051
- Testing
- Phenazopyridine Hydrochloride Tables, USP 200 mg
- Where
- United States
- Volunteers
- 424 people
- Sponsor
- Amneal Pharmaceuticals, LLC
Active, Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-blind, Placebo-controlled Clinical Study of the Oral IL-12/23 Inhibitor, STA-5326 Mesylate, Administered to Patients With Rheumatoid Arthritis to Determine Safety, Tolerability, Pharmacokinetic and Synovial Tissue Outcomes
It is not fully clear how rheumatoid arthritis originates and develops, but it is understood that multiple genetic and environmental factors interact to trigger its onset.
- Trial name
- NCT00642629
- Testing
- STA 5326 mesylate
- Where
- Netherlands
- Volunteers
- 35 people
- Sponsor
- Synta Pharmaceuticals Corp.
Emphysema or COPD
Study to Assess Safety, Feasibility, and Preliminary Efficacy of the Apreo Implant for Severe Emphysema
The goal of this clinical trial is to test the feasibility of an implant for severe emphysema in up to 30 participants at up to 5 study centers located in Europe and the United Kingdom.
- Trial name
- BREATHE-2 (NCT05949645)
- Testing
- Apreo Implant Group
- Where
- 3 sites in Austria, Netherlands and 1 more
- Volunteers
- 30 people
- Sponsor
- Apreo Health, Inc.
Palmoplantar Pustulosis
A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis
The main objective of the study is to evaluate the efficacy of twice daily applications of delgocitinib cream 20 mg/g compared with cream vehicle in the treatment of adult participants with mild to severe palmoplantar pustulosis…
- Trial name
- NCT07013201
- Testing
- Delgocitinib cream, Vehicle cream
- Where
- 40 sites in United States, Canada and 3 more
- Volunteers
- 135 people
- Sponsor
- LEO Pharma
Back Pain Lower Back Chronic
Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Low Back Pain
The objective of this study is to demonstrate the effectiveness and tolerability of the buprenorphine transdermal system (BTDS) 20 in comparison to the buprenorphine transdermal system (BTDS) 5 and oxycodone immediate-release in…
- Trial name
- NCT00313014
- Testing
- Buprenorphine, Oxycodone Immediate-Release
- Where
- 85 sites in United States
- Volunteers
- 660 people
- Sponsor
- Purdue Pharma LP
Sepsis
Effects of Voluven on Hemodynamics and Tolerability of Enteral Nutrition in Patients With Severe Sepsis
The rapidity and the quality of fluid resuscitation in patients with severe sepsis are important factors for the prevention of secondary multi-organ failure.
- Trial name
- CRYSTMAS (NCT00464204)
- Testing
- 6 % Hydroxyethylstarch 130/0.4 = "Voluven®", 0.9 % NaCl
- Where
- 24 sites in France, Germany
- Volunteers
- 196 people
- Sponsor
- Fresenius Kabi
Atopic Dermatitis
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
This trial is designed to evaluate multiple compounds in participants with moderate to severe atopic dermatitis (AD).
- Trial name
- NCT06947993
- Testing
- GHZ339
- Where
- 105 sites in United States, Argentina and 15 more
- Volunteers
- 224 people
- Sponsor
- Novartis Pharmaceuticals
Influenza, Human
A Study on the Efficacy of a Vaccine Against Influenza in Adults ≥65 Years of Age
This study will compare an investigational mRNA flu vaccine with a licensed flu vaccine in adults 65 years of age and older. Participants will receive one injection and will be followed during the flu season.
- Trial name
- NCT07805707
- Testing
- mRNA Seasonal Flu vaccine, Licensed Influenza Vaccine
- Where
- 163 sites in United States
- Volunteers
- 54,000 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Crohn's Disease
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
The primary purpose of this study was to determine the effect of vedolizumab induction treatment on clinical response and remission at 6 weeks and to determine the effect of vedolizumab maintenance treatment on clinical remission…
- Trial name
- GEMINI II (NCT00783692)
- Testing
- vedolizumab
- Where
- 114 sites in United States, Canada and 1 more
- Volunteers
- 1,116 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Tinea Pedis
Nitric Oxide Releasing Solution (NORS) Footbath to Treat Athlete's Foot
The purpose of this study is to determine the fungicidal efficacy of nitric oxide releasing solution footbath and it's effect on the clinical signs and symptoms associated with Tinea Pedis
- Trial name
- NCT02871011
- Testing
- Nitric Oxide, Water
- Where
- Canada
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Nitric Solutions Inc.
Breast Cancer
A Study to Learn About the Relationship Between Hepatic Impairment and Myelosuppression (Decreased Bone Marrow Function) in Breast Cancer Patients Treated With the Study Medicine Palbociclib (Pal-bow-sai-klib)
The purpose of this study is to evaluate incidence of grade 4 neutropenia in patients who have hepatic impairment and use the study medicine Palbociclib.This study is seeking participants: - treated with the study medicine…
- Trial name
- NCT05912933
- Where
- United States
- Volunteers
- 1,342 people
- Sponsor
- Pfizer
Atopic Dermatitis
A Study to Assess Change in Disease Activity in Adolescents and Adults With Moderate to Severe Prurigo-type Atopic Dermatitis in Japan Who Are Treated With Oral Upadacitinib
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Around one-third of patients with AD have had at least 1 incidence of prurigo nodularis (PN), which is characterized by…
- Trial name
- ADMIRE (NCT05451316)
- Where
- Japan
- Volunteers
- 1 people
- Sponsor
- AbbVie
Systemic Lupus Erythematosus
Study Evaluating the Pharmacokinetics and Safety of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE)
The primary objective of the study is to evaluate the safety, tolerability and Pharmacokinetics (PK) of Epratuzumab in Japanese subjects with moderate to severe general SLE as add on to standard of care treatment during the trial.
- Trial name
- NCT01449071
- Testing
- Epratuzumab 400 mg, Epratuzumab 1200 mg, Epratuzumab 100 mg
- Where
- 7 sites in Japan
- Volunteers
- 20 people
- Sponsor
- UCB Pharma
Rosacea
A Therapeutic Equivalence Study of Two Metronidazole 1%Topical Gel Treatments for Patients With Rosacea
The objective of this study is to demonstrate that metronidazole 1% topical gel is effective for the treatment of patients with moderate to severe rosacea.
- Trial name
- MTZG (NCT01513863)
- Testing
- Metronidazole Topical Gel 1%, Metronidazole Topical Gel 1% (Metrogel)
- Where
- 22 sites in United States
- Volunteers
- 602 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.